Table 3.

Immunohistochemical and mutational status of KIT in cases in which primary and metastatic melanoma tumors from the same patient were available for study

Case No.	Diagnosis	KIT IHC, primary tumor (site)	KIT IHC, metastasis (site)	Mutational analysis
9	Mucosal melanoma	51–95%, 1+ (anus/rectum)	>95%, 3+ (inguinal lymph node)	Not amplifiable DNA (both)
17	Mucosal melanoma	51–95%, 3+ (urethra)	51–95%, 2+ (skin)	Not amplifiable DNA (both)
20	Mucosal melanoma	>95%, 3+ (vagina)	51–95%, 2+ (inguinal lymph node)	KIT mutation, exon 17, D816V (both)
60	Acral lentiginous melanoma	51–95%, 2+ (left toe)	>95%, 3+ (skin)	KIT mutation, exon 11, V559A (both)